Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation.

ABSTRACT:

Background

The use of single-chain variable fragments (scFvs) for treating human diseases, such as cancer and immune system disorders, has attracted significant attention. However, a critical drawback of scFv is its extremely short serum half-life, which limits its therapeutic potential. Thus, there is a critical need to prolong the serum half-life of the scFv for clinical applications. One promising serum half-life extender for therapeutic proteins is human serum albumin (HSA), which is the most abundant protein in human serum, known to have an exceptionally long serum half-life. However, conjugating a macromolecular half-life extender to a small protein, such as scFv, often results in a significant loss of its critical properties.

Results

In this study, we conjugated the H

SUBMITTER: Go EB 

PROVIDER: S-EPMC10996255 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature